Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cidara Therapeutics is a clinical-stage biotechnology company developing novel antifungal and antiviral therapies using its proprietary Cloudbreak platform, which conjugates antiviral/antifungal agents to human antibody fragments for extended half-life dosing. The company's lead programs include rezafungin (antifungal in Phase 3 for candidemia/invasive candidiasis) and CD377 (universal influenza conjugate in preclinical development). With near-zero revenue, negative operating cash flow of $200M annually, and a 4.62x current ratio, the company is burning through cash reserves while advancing clinical programs, with stock performance driven entirely by clinical trial readouts and partnership announcements rather than operational fundamentals.
Cidara operates a binary-outcome business model typical of clinical-stage biotechs: monetization occurs through (1) upfront payments and milestone fees from licensing proprietary Cloudbreak conjugate technology to pharma partners, (2) government grants for pandemic preparedness programs, and (3) eventual product royalties or sales if clinical trials succeed and gain FDA approval. The 921% one-year return reflects speculative positioning around clinical catalysts rather than operational cash generation. With 100% gross margin on minimal revenue and -13,812% operating margin, the company has no current pricing power and depends entirely on capital markets access and partnership economics to fund $200M+ annual cash burn until commercialization.
Rezafungin Phase 3 trial data readouts and FDA submission timelines for candidemia/invasive candidiasis indication
Partnership announcements or expansions for Cloudbreak platform technology with major pharmaceutical companies
CD377 universal influenza program preclinical data and IND filing progress
Cash runway updates and equity financing announcements (dilution risk vs. liquidity extension trade-off)
Competitive developments in antifungal market (Scynexis BREXAFEMME, Amplyx fosmanogepix) affecting commercial opportunity perception
Binary clinical trial risk: Phase 3 rezafungin failure would eliminate primary value driver and potentially render company non-viable without significant restructuring
FDA regulatory pathway uncertainty for novel antifungal mechanisms, including potential requirement for additional safety studies or restricted labeling that limits commercial opportunity
Reimbursement environment for hospital-administered antifungals under DRG payment systems may limit pricing power even with successful approval
Pandemic preparedness funding volatility as government priorities shift away from COVID-era biodefense spending
Scynexis oral ibrexafungerp (BREXAFEMME) already approved for vulvovaginal candidiasis with IV formulation in development, creating head-to-head competition in invasive fungal infections
Amplyx fosmanogepix (if approved) and Mycovia VT-1598 represent alternative mechanisms targeting same patient populations
Major pharmaceutical companies (Pfizer, Merck, Gilead) possess substantially greater commercialization infrastructure and could in-license or develop competing assets
Cloudbreak platform faces competition from other antibody-drug conjugate technologies with established validation in oncology (ADC platforms from Seagen, Daiichi Sankyo)
Cash burn rate of $200M annually against current market cap of $5.6B implies need for additional financing within 12-18 months depending on existing cash reserves (4.62x current ratio suggests adequate near-term liquidity but not multi-year runway)
Equity dilution risk from future offerings: at current burn rate and typical biotech cash management (maintain 18-24 month runway), expect 10-20% dilution annually until revenue generation
No debt capacity given negative cash flow and lack of tangible assets for collateralization, limiting financing options to equity or dilutive convertible instruments
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations because R&D spending follows scientific timelines rather than economic cycles. However, capital markets access (equity financing ability) correlates with risk appetite during expansions vs. contractions. Hospital budgets for novel antifungals may face pressure during recessions, affecting commercial opportunity perception, but clinical trial execution continues regardless of macro conditions.
Rising interest rates negatively impact valuation through two mechanisms: (1) higher discount rates applied to distant future cash flows (rezafungin revenues unlikely before 2027-2028) compress NPV of pipeline assets, and (2) risk-free rate competition makes speculative biotech equity less attractive relative to Treasury yields. The company holds cash reserves that benefit marginally from higher short-term rates, but this is overwhelmed by valuation multiple compression. Fed funds rate increases historically correlate with biotech sector underperformance.
Minimal direct credit exposure given zero debt (0.00 Debt/Equity ratio) and no commercial lending operations. However, credit market conditions indirectly affect capital raising ability: widening high-yield spreads signal risk-off sentiment that makes follow-on equity offerings more dilutive or unavailable. Tight credit conditions could also constrain hospital capital budgets for novel therapeutics post-approval, affecting commercial forecasts.
growth/momentum - The 921% one-year return and 258% six-month return attract speculative growth investors and momentum traders positioning ahead of binary clinical catalysts. The stock appeals to biotech specialists who model probability-weighted NPV of pipeline assets rather than traditional value investors focused on cash flow generation. High-net-worth individuals and hedge funds with biotech expertise dominate the shareholder base, while institutional long-only funds typically avoid pre-revenue clinical-stage names due to binary risk profile.
high - Clinical-stage biotechs exhibit extreme volatility around data readouts (typical 30-70% single-day moves on trial results) and financing announcements. The 921% one-year return demonstrates momentum-driven price action disconnected from fundamentals. Implied volatility typically exceeds 80-100% ahead of Phase 3 readouts. Beta likely exceeds 2.0x relative to broader market, with correlation to biotech sector indices rather than S&P 500.